Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO · NASDAQ Global Market
-$0.05 today
Vol 1.08M · Avg 0.86M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:LXEO · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$87.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.45, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 -100.0% | $654.0K -60.5% | $1.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 -100.0% | $654.0K -60.5% | $1.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $63.8M -13.9% | $74.1M +39.5% | $53.1M +8.1% | $49.2M +9.0% | $45.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $45.5M +43.5% | $31.7M +105.9% | $15.4M +28.2% | $12.0M +67.3% | $7.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $109.3M +3.3% | $105.8M +54.4% | $68.5M +12.0% | $61.2M +17.0% | $52.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.1M +3.8% | $2.0M +8.6% | $1.8M +61.0% | $1.1M +8707.7% | $13.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$97.7M -1.5% | -$96.2M -49.5% | -$64.3M -10.9% | -$58.0M -14.7% | -$50.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | -8874.8% -5820.5pp | -3054.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$109.3M -3.3% | -$105.8M -54.4% | -$68.5M -13.2% | -$60.5M -19.5% | -$50.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | -9252.1% -6196.2pp | -3055.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.1M -18.9% | $7.6M +163.6% | $2.9M +116.4% | $1.3M +8733.3% | $15.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $206.0K +80.7% | $114.0K -44.4% | $205.0K +125.3% | $91.0K | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $9.3M +25.1% | $7.4M +250.8% | $2.1M +72.0% | $1.2M +8113.3% | $15.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$100.0M -1.7% | -$98.3M -48.1% | -$66.4M -12.0% | -$59.3M -17.1% | -$50.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | -9063.8% -6008.7pp | -3055.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$100.0M -1.7% | -$98.3M -48.1% | -$66.4M -12.0% | -$59.3M -17.1% | -$50.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | -9063.8% -6008.7pp | -3055.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +39.8% | -$3 -24.1% | -$2 -5.5% | -$2 -17.4% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +39.8% | -$3 -24.1% | -$2 -3.8% | -$2 -19.4% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $53.6M +68.8% | $31.8M +19.3% | $26.6M +5.9% | $25.2M +0.0% | $25.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $53.6M +68.8% | $31.8M +19.3% | $26.6M +5.9% | $25.2M +0.0% | $25.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$438.92M
DBV Technologies S.A.
NASDAQ:DBVT
$385.73M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$347.71M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$346.08M
Amarin Corporation plc
NASDAQ:AMRN
$334.13M
Silence Therapeutics plc
NASDAQ:SLN
$324.26M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$299.95M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.26M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.90M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LXEO generate?
Lexeo Therapeutics, Inc. Common Stock (LXEO) reported $0.00 of revenue in fiscal 2025.
Is LXEO profitable?
Lexeo Therapeutics, Inc. Common Stock (LXEO) reported -$99,961,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.